SeaStar Medical
About: SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Employees: 19
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
326% more capital invested
Capital invested by funds: $351K [Q4 2024] → $1.5M (+$1.14M) [Q1 2025]
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
30% more funds holding
Funds holding: 20 [Q4 2024] → 26 (+6) [Q1 2025]
6.28% more ownership
Funds ownership: 4.07% [Q4 2024] → 10.35% (+6.28%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for ICU.
Financial journalist opinion
Based on 5 articles about ICU published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients
DENVER, July 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today positive preliminary results from the SAVE Surveillance Registry which is assessing the use of the QUELIMMUNE therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT). Based on the data collected from the first 20 pediatric patients in the SAVE Surveillance Registry, there were no device related safety events with the QUELIMMUNE therapy and 75% of patients have survived through 28 days. These new data are on track to validate or potentially exceed a 50% reduction in loss of life compared to historical data, as reported in Kidney Medicine.
Neutral
GlobeNewsWire
2 weeks ago
SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry
Highest Rated Children's Medical Centers Now Employ QUELIMMUNE for Ultra-Rare Cases of Pediatric AKI HDE Surveillance Registry Data Captures Key Metrics for Future Analysis of QUELIMMUNE Performance DENVER, July 16, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company announced today that it has added a nationally-recognized, Texas-based children's hospital to its growing customer base of QUELIMMUNE therapy users. The QUELIMMUNE therapy was approved by the U.S. Food and Drug Administration in 2024 under a Humanitarian Device Exemption (HDE) to treat pediatric patients with life-threatening, ultra-rare Acute Kidney Injury (AKI) due to sepsis or a septic condition on antibiotic therapy and requiring Renal Replacement Therapy (RRT).
Neutral
GlobeNewsWire
2 weeks ago
SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
DENVER, July 10, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 5,242,464 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.763 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, SeaStar Medical will issue and sell unregistered warrants to purchase up to 5,242,464 shares of common stock. The warrants will have an exercise price of $0.638 per share, will be exercisable immediately upon issuance and will expire five years following the effective date of the resale registration statement registering the shares of common stock issuable upon exercise of the warrants.
Neutral
GlobeNewsWire
3 weeks ago
SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)
Nationally Recognized Texas Children's Hospital Adds First-In-Class Therapy as a Potential Life-Saving Treatment in Ultra-Rare Cases of Pediatric AKI Nationally Recognized Texas Children's Hospital Adds First-In-Class Therapy as a Potential Life-Saving Treatment in Ultra-Rare Cases of Pediatric AKI
Neutral
GlobeNewsWire
4 weeks ago
SeaStar Medical Announces Positive Nasdaq Listing Determination
DENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has received confirmation from The Nasdaq Stock Market that the Company has evidenced compliance with the minimum $2.5 million stockholders' equity requirement and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the previously disclosed listing matter has been closed.
Neutral
GlobeNewsWire
1 month ago
SeaStar Medical Reports Update on Nasdaq Listing Status
DENVER, June 25, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that it has undertaken a series of transactions to ensure compliance with Nasdaq's continued listing standards.
Neutral
GlobeNewsWire
1 month ago
SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
Cincinnati Children's Hospital Medical Center Discusses QUELIMMUNE Therapy Adoption A Father and Patient Describe Their Real-Life Experience with the QUELIMMUNE Therapy DENVER, June 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that the QUELIMMUNE therapy will be featured in a two-part video series that will be available on the SeaStar Medical website. The videos describe the adoption and the use of the QUELIMMUNE therapy for pediatric patients at the nationally recognized Cincinnati Children's Hospital Medical Center and an interview with a father and his son, a pediatric patient in the ICU at Cincinnati Children's who experienced a rapid recovery to good health following the use of the QUELIMMUNE therapy.
Neutral
GlobeNewsWire
1 month ago
SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants $4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Neutral
GlobeNewsWire
1 month ago
AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research
SAN ANTONIO, Texas and DENVER, Colorado, June 11, 2025 (GLOBE NEWSWIRE) -- The Autonomous Reanimation and Evacuation (AREVA) Research Institute and SeaStar Medical (Nasdaq: ICU) announced today that a new United States Department of Defense (DoD) grant has been awarded to AREVA. The grant is one of four selected out of 160 total submissions by the 2024 Military Burn Research Program (MBRP) and represents cutting-edge research for extracorporeal immunomodulation to reduce inflammation after severe burns, inhalation injury, and septicemia.
Neutral
GlobeNewsWire
2 months ago
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
Coverage marks SeaStar Medical's second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial
Charts implemented using Lightweight Charts™